Literature DB >> 14654793

Chfr inactivation is not associated to chromosomal instability in colon cancers.

Jacques Bertholon1, Qing Wang, Nicole Falette, Carole Verny, Jessie Auclair, Christelle Chassot, Claudine Navarro, Jean-Christophe Saurin, Alain Puisieux.   

Abstract

Numerous observations suggest that chromosome instability is caused by mitotic abnormalities such as errors in the partitioning of chromosomes. Chfr was recently defined as a central component of a new mitotic checkpoint that delays chromosome condensation in response to mitotic stress. Chfr was shown to be frequently inactivated in several human neoplasms, including colon, lung and esophageal cancers. To test whether Chfr inactivation may lead or participate to chromosomal instability (CIN), we analysed the genetic and epigenetic status of the gene in a large panel of primary colon and breast cancers, as well as in colon and breast cancer cell lines displaying either a microsatellite instability or a CIN. Our results confirm that Chfr is frequently inactivated in colon cancers, through a mechanism of hypermethylation of the promoter sequences. In contrast, the loss of Chfr expression appears to be a rare event in breast cancers. Furthermore, our data demonstrate that Chfr inactivation is not associated with CIN in these frequent types of human cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14654793     DOI: 10.1038/sj.onc.1207078

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

Review 1.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

Review 2.  CHFR: a key checkpoint component implicated in a wide range of cancers.

Authors:  Sheru Sanbhnani; Foong May Yeong
Journal:  Cell Mol Life Sci       Date:  2011-12-13       Impact factor: 9.261

Review 3.  Epigenetic insights in the diagnosis, prognosis, and treatment selection in CRC, an updated review.

Authors:  Farzaneh Ghadiri Moghaddam; Safar Farajnia; Mohammad Karbalaei-Mahdi; Laleh Monir
Journal:  Mol Biol Rep       Date:  2022-06-21       Impact factor: 2.742

4.  Yeast Chfr homologs retard cell cycle at G1 and G2/M via Ubc4 and Ubc13/Mms2-dependent ubiquitination.

Authors:  Greta L Loring; Kathryn C Christensen; Scott A Gerber; Charles Brenner
Journal:  Cell Cycle       Date:  2007-10-02       Impact factor: 4.534

5.  CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.

Authors:  Lorraine Pelosof; Sashidhar R Yerram; Nita Ahuja; Andrew Delmas; Ludmila Danilova; James G Herman; Nilofer S Azad
Journal:  Int J Cancer       Date:  2013-08-24       Impact factor: 7.396

6.  CHFR: A Novel Mitotic Checkpoint Protein and Regulator of Tumorigenesis.

Authors:  Lisa M Privette; Elizabeth M Petty
Journal:  Transl Oncol       Date:  2008-07       Impact factor: 4.243

7.  Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer.

Authors:  Eiji Oki; Yan Zhao; Rintaro Yoshida; Takanobu Masuda; Koji Ando; Masahiiko Sugiyama; Eriko Tokunaga; Masaru Morita; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  World J Gastroenterol       Date:  2009-05-28       Impact factor: 5.742

8.  Chfr and RNF8 synergistically regulate ATM activation.

Authors:  Jiaxue Wu; Yibin Chen; Lin-Yu Lu; Yipin Wu; Michelle T Paulsen; Mats Ljungman; David O Ferguson; Xiaochun Yu
Journal:  Nat Struct Mol Biol       Date:  2011-06-26       Impact factor: 15.369

9.  The anti-proliferative effects of the CHFR depend on the forkhead associated domain, but not E3 ligase activity mediated by ring finger domain.

Authors:  Tomokazu Fukuda; Yasuyuki Kondo; Hitoshi Nakagama
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240

Review 10.  Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.

Authors:  Sarah Derks; Arjen H G Cleven; Veerle Melotte; Kim M Smits; Johann C Brandes; Nilofer Azad; Wim van Criekinge; Adriaan P de Bruïne; James G Herman; Manon van Engeland
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.